General anxiety in humans is treated with azaspirodecanedions, which act through a reduction of serotonin transmission. Ipsapirone also represents a serotonin (5-HT,,) receptor agonist and was under development as an anxiolytic drug. Histopathologic evaluation of animal experiments revealed cellular swelling andor vacuolation of renal papillary and medullary collecting duct (MCD) epithelium in rats but not in dogs or mice. The changes ensued already after 1 wk of dosing and were first localized in the inner MCDs. Longer treatment periods showed that these changes proceeded from proximal to distal, approaching the papillary collecting ducts. The changes were most likely the result of altered hemodynamics in the papillary tip. Swelling resulted in partial or total papillary necrosis in some cases. Furthermore, rats treated with ipsapirone showed a sharp and transient rise in urinary endothelin excretion. Concomitantly, urinary PGE, levels were elevated. In contrast, no elevated levels of endothelin were detected in urine samples of patients from a volunteer study, leading to the conclusion that the human kidney is not susceptible to the ipsapirone-induced alterations seen in the collecting ducts of rats. secondary effect due to the swelling and the resulting altered hemodynamics of the papillary tip. Other studies were undertaken to prove the role of hormonal influences, e.g., vasopressin, endothelin, and prostaglandin E2 (PGE,). This paper summarizes the results from the extensive histopathologic investigations.
INTRODUCTION
General anxiety in humans has long been treated with benzodiazepines such as chlordiazepoxide, diazepam, or oxazepam (10, 24) . Benzodiazepines, however, have some undesirable side effects such as sedation, habituation, withdrawal hyperexcitability, and interaction with other sedatives. Moreover, there is a high risk for abuse (15) . A relatively novel class of compounds acting through a reduction of serotonin transmission was introduced to the market. These so-called azaspirodecanedions are effective in relief of anxiety and are better tolerated. Their mode of action is attributed mainly to stimulation of the 5-HTlA subtype of serotonin receptors (22) . Buspirone is considered to be the prototype of this compound class (30) . Ipsapirone represents also a serotonin (5-HT,,) receptor agonist and was recently under development as an anxiolytic drug. Both ipsapirone and buspirone share the same endogenous metabolite 1-(2-pyrimidinyl)-piperazine (1-PP).
During the developmental period of ipsapirone, uncommon histopathologic findings in the kidneys of rats raised concern. These were swelling andor vacuolation of the papillary and medullary collecting duct (MCD) cells and the occurrence of partial or total papillary necrosis in a number of cases. An extensive battery of mechanistic experiments followed the standard toxicity guideline studies to elucidate the relevance of the findings for the human patient. Thus, it was the aim of some studies to clarify whether the observed papillary necrosis represented a primary effect of a possible papillotoxin or a MATERIAL AND METHODS Due to the great variety of studies reported in this paper, it is reasonable to give only a comprehensive overview of the materials and methods used. All studies were performed following the current German law on the protection of animals.
Aiiiinals. During the developmental period of ipsapirone, the majority of experiments was carried out in young adult male and female Wistar rats (5 to 8 wk old) of the strain B0R:WISW (Cpb/SPF) derived from Winkelmann, Borchen, Germany. Studies addressing the role of vasopressin (AVP) were carried out in AVP-deficient Brattleboro rats obtained from Harlan CPB, the Netherlands.
Cliiiical Iiivestigatioiis. All animals were housed individually under controlled conditions as recommended in OECD guidelines for toxicity studies. Depending on the study design, the animals were fed a standard diet (Altromin 1321). During the studies body weight gain and feed or water intake were determined where appropriate. Standardized clinicolaboratory methods were used to examine blood or urine samples.
Test Material arid Dose Regiiiieii. Ipsapirone (2-(4-(2-pyrimidiny1)-1 -piperazinyl-buty1)-1,2-benziso-thiazol-3 (2H) one-1.1. dioxide-hydrochloride) ( Fig. 1 ) was administered using different routes and dosages: in total, three 152 2-year studies were performed in rats. Single oral administration was given by gavage (up to 300 mgkg/day); during studies with repeated administration, the compound was mixed either into the diet (up to 4,500 ppm) or the drinking water (up to 1,500 ppm) and offered for the study period. Apart from the guideline studies demanded for registration, a variety of mechanistic studies was carried out. Since 4,500 ppm of ipsapirone in the feed was recognized to give reproducible results with respect to the kidney findings, this dose was chosen for most of the mechanistic studies. Additionally, in some studies the drinking water was enriched with either NaCl, NH,Cl, NaHCO,. or KCL. The metabolite 1-PP ( Fig. 2 ) was administered to rats by gavage in dosages of 300 and 600 mgkg for 10 days. To reproduce papillary necrosis, adult female Wistar rats were injected intraperitoneally with a single dose of 50 mgkg body weight of 2-bromethylamine (BEA).
Pathology Studies. All animals subjected to histopathologic examination were sacrificed under deep anesthesia by exsanguination. With the exception of long-term experiments in which all organs were fixed in 10% buffered formaldehyde solution, the kidneys obtained from all other studies were fixed in Bouin's fluid. The kidneys were trimmed transversally, embedded in paraffin, cut at thickness of approximately 4 pm, and stained with hematoxylin and eosin (H&E) and the periodic acid-Schiff (PAS) reaction. Special attention was given to the fact that the complete papilla, including the papillary tip, was available in at least one of both kidney slides.
Phase I Stridy. Thirty-six healthy male volunteers participated in phase 1 of the ipsapirone study (12 placebo, age 28 & 9 yr; 24 verum, age 30 -I 10 yr). The patients received 20 mg of ipsapirone per day for the first 7 days. Then the dose was increased by 10 mg and kept constant for the next 7 days. This incremental increase was repeated 3 times. The study ended after 5 wk with a daily dose of 60 mg of ipsapirone per person in the fifth week.
Total daily urine was collected at several time points during the study. For endothelin and creatinine determi- nations, urine samples were taken from the first week (20-mg dose) and the last week (60-mg dose). Creatinine was determined according to a standardized clinicolaboratory method. Endothelin (ET) and PGE, were measured by a radioimmunoassay (Amersham, Germany).
RESULTS

Clinical Observations
A number of studies were carried out to investigate the toxic potential of ipsapirone (Table I) . For clarity, clinical observations only of the 3 long-term studies in rats are summarized here.
Siirvival Rate. Survival was not affected in all 3 chronic studies. However, animals treated with high doses of ipsapirone more often showed a poor physical condition.
Body Weight. Generally, rats treated with high doses of ipsapirone showed reduced body weights in all experiments.
Feed Intake. In both the 2-yr feeding and the 2-yr gavage studies, feed intake was reduced in treated animals. However, if calculated in relation to body weight, feed intake was increased in both sexes of the high-dose group. In the chronic drinking water study, food consumption was markedly reduced in the high dose (about 10% in males and 17% in females).
Water Intake. In the chronic feeding study, water intake was comparable to controls in treated males. However, calculation in relation to the body weight revealed a dose-related increase. A reduced water intake was observed in treated females even if calculated in relation to body weight. Water intake was reduced in all treated animals of the chronic drinking water study. This was more pronounced in females than in males. The marked reduced water intake may be explained in part by a reduced palatability of the drinking water.
Heiliatology and Clinical Chemistry. High-dose animals showed lowered numbers of erythrocytes and concomitant decreases in hemoglobin and hematocrit. Serum liver enzymes alanine-arginine-transferase (ALAT) and alkaline phosphatase (APh) were markedly increased in high-dose animals, indicating liver toxicity. Statistically increased blood urea nitrogen levels were observed in high-dose males and mid-and high-dose females. Protein and albumin concentrations of peripheral blood were significantly reduced in treated animals of both sexes.
Uririalysis. Reduced urine flow with a correspondingly increased urinary osmolality and a decreased urinary electrolyte excretion, especially of urinary calcium and phosphate, were observed in the majority of the studies in animals of the high-dose group. No signs of protein loss were detected in the urine. Hematuria was observed in high-dose males and high-and mid-dose females of the chronic drinking water study. In addition, the increased urinary excretion of lactate dehydrogenase (LDH) indicated kidney damage.
Pathology Stitdies
An overview of toxicity studies conducted in the developmental period of ipsapirone is given in Table I . In the studies carried out in dogs and mice, no remarkable kidney findings were noted. In most of the rat studies, animals treated with high doses of ipsapirone showed a poor physical condition and emaciation more often. Generally, no gross effects on the kidneys associated with the treatment with ipsapirone were observed at necropsy. The only exception was a higher incidence of kidneys with a rough surface seen in males of the high-dose group at the end of the chronic feeding study. Histopathologically, uncommon kidney findings were seen. These consisted of epithelial swelling andor vacuolation of the MCD cells (MCDC) and renal papillary necrosis (RPN).
Epithelial Swelling arid Vacirolation of the MCDC
Epithelial swelling and vacuolation of the MCDC were observed in rats of the standard toxicological studies. In a subchronic feeding study, they were seen in both sexes of the mid-and high-dose group (Table 11) . After 1 yr, swelling and vacuolation were also observed in the interim sacrifice groups of a 2-yr feeding study involving the same dose levels (Table 111) . At the end of the 2-yr feeding period, severe swelling, vacuolation, and sometimes degeneration of MCDC were noted in nearly all males of the 1,500-and 4,500-ppm dose groups and in 80% of the females of the high-dose group (Table 111) . This change was characterized by ballooning degeneration of epithelial cell cytoplasm with peripheral displacement of the nuclei (Fig. 3) . Many of the degenerated epithelial cells showed a central condensation of cytoplasm, which was markedly eosinophilic and stained positive in the PAS reaction. There was also a loss of epithelial cells into the lumen as well as rupture of degen- erate cells with and without extrusion of cell contents into the lumen. In extreme cases, the tubular lumen even seemed to be occluded due to the protrusion of ballooned cells.
To gain further insight into the nature of the ipsapirone-induced changes, a number of additional mechanistic studies were initiated.
Animals treated with 0, 500, 1,500, and 4,500 ppm ipsapirone in the feed and then sacrificed after 1, 5, and 9 weeks of treatment produced interesting results concerning the first occurrence of MCDC swelling. After 1 wk of dosing 1,500 ppm to males and 4,500 ppm to females, cellular swelling and vacuolation of the inner MCDs at the papillary base were noted. After longer treatment periods, the change spread to the papillary tip. After 5 wk, the proximal half of the papilla was involved. The slides of the animals from the ninth week's necropsy revealed that the distal half of the papilla was reached; vacuolar changes in the papillary tip were an exception. Furthermore, slight to moderate tubular dilation was observed within the cortex and the medulla of single animals. Additionally, areas of increased basophilic tubules in the renal cortex were seen in some animals, and a slight increase in intra-or extravascular round cell infiltration was noted in the cortical areas.
The renal site of morphological and physiological changes (frequently decreased water intake, urine flow, and urinary electrolyte excretion and increased urinary osmolality) observed after administration of high doses of ipsapirone suggested that changes in hormonal regulation of body fluid balance, especially the antidiuretic hormone arginine-vasopressin (ADH-AVP), might be involved into the development of the alterations described. The possibility that ipsapiron could act like ADH and thereby increase the water reabsorption was investigated using Brattleboro rats. Due to a defective gene locus next to the ADH gene, Brattleboro rats are unable to release ADH into the blood on demand. Lacking free ADH in the blood, they exhibit the clinical signs of a diabetes insipidus, i.e., the excretion of large amounts of a highly diluted urine.
In a 13-wk study with dosages of 4,500 ppm ipsapirone in the feed, Brattleboro rats revealed clinical signs similar to those seen in Wistar rats: reduced body weight gain, reduced water intake, and slightly decreased urine flow. Moreover, histopathologic examination revealed the same vacuolar changes in the collecting duct epithelium. Remarkable, however, was an increased amount of PASpositive material in the papillary tip (Fig. 4) .
To prove the role of the metabolite, Wistar rats were treated with 300 and 600 mgkg 1-PP by gavage for 10 days. Marked swelling and vacuolation, sometimes even more pronounced compared with the treatment with ipsapirone, were observed in animals of both dose groups.
Finally, since literature gave hints that vacuolar swelling of MCDC and the occurrence of PAS-positive granules in the MCDC are associated with potassium depletion, ipsapirone-treated animals received equimolar concentrated salt drinking solutions containing either NaCl, KCl, NH4Cl, or NaHCO,. Surprisingly, nearly all animals revealed no vacuolar swelling of MCDC. Moreover, urinalysis and clinical chemistry revealed no remarkable change of potassium levels (Table IV) . 
Popillmy Necrosis
In a subchronic study, single animals of the 4,500-ppm dose group developed early necrotic alterations of the papillary tip away from the zone of vacuolar changes of the collecting ducts. In 1 animal it was formed by an interstitial area with poorly recognizable structures (necrobiosis or patchy loss of staining detail; Fig. 5) . while in a second animal a complete hemorrhagic necrosis of the papillary tip was noted. Further signs indicating treatment-related papillary damage were seen after a 6-mo drinking-water study in Wistar rats with dosages of 0, 100, 300, and 1,000 ppm (Table V) . Changes were seen in the renal papilla of about a quarter of the female animals of the mid-and the high-dose group and in few males of the high-dose group. These were small focal areas of interstitial eosinophilic swelling associated with slight hyperemia in some cases but without any accompanying cellular reaction. Because these lesions bore some resemblance to the patchy loss of staining detail described by Elliott (7), they were considered to represent early stages of focal (subepithelial) papillary necrosis.
Changes comparable to the alteration seen in the TOXICOLOGIC PATHOLOGY above-mentioned 6-mo drinking water study were seen at the end of the 2-yr feeding study. Again, these were focal interstitial papillary changes, including an eosinophilic swelling with loss of structural detail, hyperemia and focal hemorrhage followed by partial or complete papillary necrosis (Fig. 6) . Focal interstitial eosinophilic swelling was observed in females of all treatment groups of the chronic feeding study with increasing incidences and in a few males of the mid-and high-dose group. Dose-related focal papillary necrosis was seen only in . females of the mid-and high-dose group and complete papillary necrosis in females of the high-dose group only (Table V) .
A study with BEA administered intraperitoneally to female rats was conducted to prove whether changes comparable to those seen in the studies with ipsapirone would arise. However, only the expected characteristic necrotic changes in the papillary tip were seen, while no alterations of the MCDs or papillary collecting ducts could be detected.
A further approach to clarify the origin of the uncommon findings in the renal papilla was to prove the role of ET. ET represents a peptide hormone to which a multitude of physiological effects is ascribed. An important feature is its involvement in renal processes; for example, ET has been shown to induce natriuresis by a mechanism that is believed to function via the inhibition of Na+-K+-ATPase.
Urine samples of Wistar rats treated with 4,500 ppm ipsapirone in the feed were analyzed for ET, PGE,, and creatinine. Urinary excretion of ET (relative to creatinine) showed a sharp and transient rise on day 2. Following this, the urinary excretion of PGE, (relative to creatinine) peaked on day 3. While the ET increase was approximately 220%. PGEz was elevated by approxi-mately 500%. In addition, urinary AVP excretion was again increased by 190%. In contrast, no elevated levels of ET could be detected in human urine samples collected in a volunteer phase 1 study. However, the doses that had been administered to the patients were at least 400 times smaller than those that had been employed in the toxicologic study.
DISCUSSION
Treatment with high doses of ipsapirone leads to physiological and morphological alterations in the rat kidney. Morphologically, 2 main histopathologic patterns of alteration can be distinguished occurring at different levels of the renal papilla during different phases of the treatment period. These are pronounced vacuolar swelling of the MCD epithelium and RPN.
Vacuolar Swelling of Mediillary Collecting Duct Epitlieliiun
To our knowledge, vacuolar swelling of MCDs and papillary collecting ducts of rats has only rarely been described in the literature. Hansen et a1 (12) reported extensive swelling of the epithelium of the collecting ducts in potassium-depleted Sprague-Dawley rats with and without metabolic alkalosis. However, in their study the finding was generally confined to the outer medullary segments of the collecting ducts. The morphology of hypokalemic nephropathy has been described also by other investigators (20, 21, 26) . Consistently, all investigations identified swelling and sometimes degeneration of epithelial cells of the outer MCDs, while vacuolar swelling was never described extending toward the papilla or even the papillary tip such as after treatment with ipsapirone.
Intracellular PAS-positive staining material in swollen cells as well as in collecting duct cells distally to the vacuolated epithelia was identified in most of the studies with ipsapirone. A similar feature was noted in cells of the papillary tip after 1 day on a low-potassium diet. With continuing potassium depletion, droplets that were increased in size and number appeared in cells from the papillary tip to the corticomedullary junction (26) . In the case of the treatment with ipsapirone, however, urinalysis and clinical chemistry revealed no hints of a potassium depletion or deficiency.
The site of the alterations observed after treatment with high doses of ipsapirone suggested that hormonal regulations of body fluid balance were involved. Since AVPdeficient Brattleboro rats revealed the same morphological changes in the kidneys as Wistar rats, it was concluded that increased plasma levels of AVP (as observed in normal rats) were not the causative factor. Furthermore, it could be stated that an increased tubular fluid flow, which in Brattleboro rats exceeded that of Wistar rats markedly, did not protect against the development of vacuolar changes (1 8).
The metabolite 1 -PP produced morphologically the same vacuolar changes in the MCDC as did ipsapirone. Therefore, it was reasonable to assume that other 5-HT,,receptor agonists that share the same metabolite (e.g., buspirone) would produce this finding. In fact, it could be shown that buspirone given to Wistar rats revealed vacuolar changes of the MCDC, though less pronounced (18). The possible role of 1-PP in rats is further supported by the observation that other agonists that do not share the metabolite 1-PP do not induce cellular swelling andor vacuolation (30). not reveal any alteration in the kidney after administration of diphenylamine, while the hamsters developed a total FU". From this was interferred that selective renal papillary concentration of xenobiotics by the countercurrent mechanism plays a negligible role in the induction of the lesion, at least for this compound (17) .
To prove whether vacuolar changes such as those seen in the studies with ipsapirone would arise, we reproduced papillary necrosis in a study using BEA. However, only the characteristic necrotic changes in the papillary tip were seen. Neither in this study nor in the references cited above did swelling or vacuolation of the MCDs or papillary collecting ducts occur. Thus, it was concluded that the development of the morphological changes seen after ipsapirone were different from those of analgesic nephropathy and mimicked by treatment with BEA.
The renal papilla is a very vulnerable region and strongly dependent of the, blood flow available (19). Since the vacuolar changes were observed starting in the base of the papilla and then with continuing time of treatment decreasing toward the papillary tip, it is reasonable to assume that the necrotic changes seen in the papillary tip after treatment with ipsapirone represent a secondary effect probably due to an ischemia and not a primary toxic effect on this part of the kidney. This is supported by the observation that early alterations in the papillary tip occur after 14 wk of treatment with ipsapirone, the time when the vacuolation has reached the distal region of the papillary tip (Table VI) .
Comparison to other Species arid Extrapolation of Findings to Huiitairs
The occurrence of vacuolar swelling of collecting duct epithelium seems to be specific for the rat, since no comparable alteration was seen either in dogs nor in mice, although the latter species received dosages about 10 times higher than those administered to rats. Since kidney morphology and function (e.g., urinary concentration ability, ratio of short vs long loops of Henle, vasculature, etc.) do not differ much between rats and mice (16) , the observed species-specific differences can probably not be attributed to differences in kidney morphology and function alone.
Anatomically, the human kidney is different from the rodent kidney, which is an unipapillate kidney. The renal papilla of'the rat is longer than the papilla of other species, and its tip extends over the base of the renal cortex, where it is enclosed by the ureter. This obviously makes the rat renal papilla more vulnerable compared to other species that possess multipapillate kidneys, e.g., the human.
As could be shown, urinary excretion of ET (relative to creatinine) showed a sharp and transient rise on day 2 followed by an increased urinary excretion of PGE, (relative to creatinine) on day 3 in rats but not in humans.
On the basis of these data, it was concluded that ET could be involved into the emergence of the cellular swelling (14) . ET acts as an inhibitor of the Na+-K+-ATPase in collecting duct epithelial cells (29) , the action of which is mediated by PGE,. Following inhibition of the Na+-K+-ATPase, intracellular Na+ levels rise while K+ levels possibly decrease (25) . However, induced natriuresis, as described for ET, was never seen in all studies with ipsapirone. Moreover, since no elevated levels of ET were detected in urine samples of patients of a volunteer study, this leads to the conclusion that the human kidney is not susceptible to ipsapirone-induced alterations seen in the collecting ducts of rats even though the doses that had been administered to the patients were at least 400 times smaller than those that had been used in the rat toxicological study.
